A 2-part Phase 1/2 Open-label Trial on ODM-212

Phase 1/2 Recruiting 229 enrolled Orion Corporation, Orion Pharma

Non-randomizedSequentialOpen-labelTreatment

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

Evaluation	Drug	Modality	Dose	Route
Subject	ODM-212	Unknown	40 mg	—
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Ipilimumab	Monoclonal antibody	1 mg/kg	Intravenous
Background	Nivolumab	Monoclonal antibody	360 mg	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous
Background	Sotorasib	Small molecule	960 mg	Oral